<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760474</url>
  </required_header>
  <id_info>
    <org_study_id>A0081211</org_study_id>
    <nct_id>NCT00760474</nct_id>
  </id_info>
  <brief_title>An fMRI Study Of Brain Response In Patients With Fibromyalgia</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Cross-Over Study In Fibromyalgia Subjects To Examine Effects Of Pregabalin On Brain Response To Mechanical Pain As Assessed By Functional Magnetic Resonance Imaging, Proton Magnetic Resonance Spectroscopy And Subjective Ratings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore how pregabalin works in patients with fibromyalgia by
      evaluating brain imaging signals. To find out whether fMRI (functional magnetic resonance
      imaging) is an efficient way to show whether new pain medications are effective in treating
      fibromyalgia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS)</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>Single voxel spectra obtained from the anterior and posterior right insula at rest to compare ratios for Gln/Cr, Glu/Cr, and combined Glutamate + Glutamine (Glx/Cr) for pregabalin and placebo. Gln, Glu, Glx calculated as ratios to the internal standard creatine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals in Response to Blunt Pressure Pain: Percent Change in BOLD Activations Including Outliers</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>BOLD fMRI imaging modality to assess brain activation signals across the whole brain in defined Region of Interest (ROI) brain regions in response to blunt pressure pain; acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kilograms [kg] pressure/equal stimulus conditions, and high pain pressure/up to 10 kg). Estimated as magnitude (percent change) of the betas representing brain signal activation associated with pressure induced pain. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals in Response to a Control Visual (Checkerboard) Stimuli</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>BOLD fMRI imaging modality to assess brain activation signals across the whole brain in defined ROI brain regions in response to checkerboard visual stimuli (flashing at 8 hertz [Hz]). Reported as percent change between the pre-dose (baseline) and post-dose values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resting State Brain Activity (Connectivity Analysis) Assessed by Temporal Correlations in Low Frequency fMRI BOLD Signals Across Pain Processing Regions</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>Resting state brain activity assessed for correlation of brain seed region (pIns, anIns) to ROI connectivity at baseline (pre-dose) and post-dose (pre minus post) measured using z-score (mean of 0, standard deviation [SD] of 1); range approximately -3 to +3. Positive (+) z-scores reflect greater connectivity (+correlation between seed region and ROI). Negative (-) z-scores reflect -connectivity (anti-correlation between seed region and ROI). ROIs include PCC and IPL from within the default mode network (DMN). DMN is a constellation of regions in which connectivity is augmented in fibromyalgia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gracely Box Scales for Pain Intensity (GBSint) Including Outliers</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>Minimum and maximum pain intensity acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kg pressure/equal stimulus conditions, and high pain pressure/up to 10 kg) measured during fMRI and scored from 0 (no pain sensation) to 20 (extremely intense). Baseline and Post-dose data for Period 1 and Period 2 summarized as Least Squares Mean (LS Mean). Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gracely Box Scales for Pain Unpleasantness (GBSunp) Including Outliers</measure>
    <time_frame>Baseline/Pre-dose (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>Minimum and maximum pain unpleasantness acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kg pressure/equal stimulus conditions, and high pain pressure/up to 10 kg) measured during fMRI and scored from 0 (neutral) to 20 (very intolerable). Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: 7 Day Average Pain Score Including Outliers</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The 7 day average pain score was defined as the mean daily pain NRS value for the last 7 days prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: 3 Day Average Pain Score Including Outliers</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The 3 day average pain score was defined as the mean daily pain NRS value for the last 3 days prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: Individual Daily Pain Score Including Outliers</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The individual daily pain score was defined as the final score recorded in the last pain diary of the treatment period 24 hours prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form McGill Pain Questionnaire (SF-MPQ): Affective Total Score Including Outliers</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12); higher scores indicated higher pain/impact. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form McGill Pain Questionnaire (SF-MPQ): Sensory Total Score Including Outliers</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12); higher scores indicated higher pain/impact. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-Form McGill Pain Questionnaire (SF-MPQ): Overall Score Including Outliers</measure>
    <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
    <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by the participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12). Total (overall) score was sum of items 1 to 15, range 0 to 45; higher scores indicated higher pain/impact. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sphygmomanometry Evoked Allodynia in Relation to the Blood Pressure (BP) Value at Which Allodynia Was Evoked</measure>
    <time_frame>Day 58</time_frame>
    <description>BP cuff evoked allodynia assessed based on participant response to the following question &quot;When I take your blood pressure, tell me if the cuff's pressure is painful&quot;. A standard BP cuff was inflated at approximately 10 millimeters of mercury (mm Hg) per second up to 180 mm Hg or to point when participant experienced pain; performed 3 times on each arm whether or not pain was reported. If no pain elicited at 180 mm Hg, it was recorded that no sphygmomanometry-evoked allodynia occurred. If pain was reported, value (in mm Hg) at which pain first occured was recorded for each of the assessments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at the Bilateral Epicondyle Tender Points Assessed Using American College of Rheumatology (ACR) Classification Criteria</measure>
    <time_frame>Day 58</time_frame>
    <description>Participant rated severity of pain upon application of 4 kilograms (kg) pressure via dolorimeter at the bilateral epicondyle tender points (2 tender points, 2 centimeters distal to the epicondyles) described in the American College of Rheumatology (ACR) classification criteria and scored on a 0 (no pain) to 10 (worst possible pain) rating scale. Each arm was to be assessed for any pain (one point on each arm) with the application of pressure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Pregabalin, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin, then placebo</intervention_name>
    <description>Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.</description>
    <arm_group_label>Pregabalin, then placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, then pregabalin</intervention_name>
    <description>Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.</description>
    <arm_group_label>Placebo, then pregabalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women must have pain due to fibromyalgia

          -  Fibromyalgia must have been diagnosed at least 6 months prior to be eligible for this
             study

        Exclusion Criteria:

          -  Patients with severe depression or other serious illness, who are left-handed, or who
             are pregnant or nursing are not eligible for this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081211&amp;StudyName=An%20fMRI%20Study%20Of%20Brain%20Response%20In%20Patients%20With%20Fibromyalgia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <results_first_submitted>March 7, 2012</results_first_submitted>
  <results_first_submitted_qc>March 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 4, 2012</results_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibromyalgia; fMRI; pain; pregabalin; Lyrica; imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants who met entrance criteria received placebo for 1 week (Day 1 to 8) then were randomized in a 1:1 ratio to blinded treatment sequence.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin First, Then Placebo</title>
          <description>Pregabalin 75 milligrams (mg) by mouth (PO) twice daily (BID) Period 1/Day 9 to 11; 150 mg BID Day 12 to 16; 200 mg BID Day 17 to 19; 225 mg BID Day 20 to 22 followed by taper Day 23 to 29 and an 8-day placebo washout period. Then, placebo matching study treatment in a similar pattern was administered beginning Period 2/Day 38.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Pregabalin</title>
          <description>Placebo matching study treatment was administered beginning Period 1/Day9. Then, Pregabalin 75 mg BID Period 2/Day 38 to 40; 150 mg BID Day 41 to 45; 200 mg BID Day 46 to 48; 225 mg BID Day 49 to 51 followed by placebo taper Day 52 to 58.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (P1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="13">1 participant discontinued in P1; re-entered with new identification number and completed P1, P2.</participants>
                <participants group_id="P2" count="14">1 participant discontinued in P1; re-entered with new identification number and completed P1, P2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Overall Number of Unique Participants</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued then re-entered</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Placebo Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (P2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Participants who met entrance criteria received placebo for 1 week (Day 1 to 8) then were randomized in a 1:1 ratio to blinded treatment sequence to receive either:
Pregabalin, then placebo: Pregabalin 75 mg PO BID Period 1/Day 9 to 11; 150 mg BID Day 12 to 16; 200 mg BID Day 17 to 19; 225 mg BID Day 20 to 22 followed by taper Day 23 to 29 and an 8-day placebo washout period. Then, placebo matching study treatment in a similar pattern was administered beginning Period 2/Day 38 and included dose escalation through Day 51 followed by placebo taper Day 52 to 58.
Or placebo, then Pregabalin: Placebo matching study treatment was administered in a similar fashion to Pregabalin treatment beginning Period 1/Day 9 and included dose escalation, taper and an 8-day placebo washout period. Then, Pregabalin 75 mg BID Period 2/Day 38 to 40; 150 mg BID Day 41 to 45; 200 mg BID Day 46 to 48; 225 mg BID Day 49 to 51 followed by placebo taper Day 52 to 58.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <description>Female</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS)</title>
        <description>Single voxel spectra obtained from the anterior and posterior right insula at rest to compare ratios for Gln/Cr, Glu/Cr, and combined Glutamate + Glutamine (Glx/Cr) for pregabalin and placebo. Gln, Glu, Glx calculated as ratios to the internal standard creatine.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>Full Analysis Set (FAS) all participants who received a minimum fixed dose of 300 mg/day of study treatment. N=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Glutamine/Creatine (Gln/Cr) and Glutamate/Creatine (Glu/Cr) Ratios Measured by Proton Magnetic Resonance Spectroscopy (1H-MRS)</title>
          <description>Single voxel spectra obtained from the anterior and posterior right insula at rest to compare ratios for Gln/Cr, Glu/Cr, and combined Glutamate + Glutamine (Glx/Cr) for pregabalin and placebo. Gln, Glu, Glx calculated as ratios to the internal standard creatine.</description>
          <population>Full Analysis Set (FAS) all participants who received a minimum fixed dose of 300 mg/day of study treatment. N=number of participants with analyzable data at observation.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glu/Cr ratio posterior insula - pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1751" spread="0.119537"/>
                    <measurement group_id="O2" value="1.13253" spread="0.123897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glu/Cr ratio posterior insula - post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1046" spread="0.14180"/>
                    <measurement group_id="O2" value="1.17129" spread="0.151535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gln/Cr ratio posterior insula - pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5311" spread="0.117359"/>
                    <measurement group_id="O2" value="0.52635" spread="0.143649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gln/Cr ratio posterior insula - post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4857" spread="0.14534"/>
                    <measurement group_id="O2" value="0.51553" spread="0.147882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glx/Cr ratio posterior insula - pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70624" spread="0.177312"/>
                    <measurement group_id="O2" value="1.65894" spread="0.215505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glx/Cr ratio posterior insula - post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5903" spread="0.19461"/>
                    <measurement group_id="O2" value="1.68747" spread="0.227398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glu/Cr ratio anterior insula - pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22731" spread="0.154333"/>
                    <measurement group_id="O2" value="1.23788" spread="0.183282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glu/Cr ratio anterior insula - post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2393" spread="0.22290"/>
                    <measurement group_id="O2" value="1.18524" spread="0.164847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gln/Cr ratio anterior insula - pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53144" spread="0.115606"/>
                    <measurement group_id="O2" value="0.47882" spread="0.143684"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gln/Cr ratio anterior insula - post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5290" spread="0.19367"/>
                    <measurement group_id="O2" value="0.47541" spread="0.100247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glx/Cr ratio anterior insula - pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75888" spread="0.164256"/>
                    <measurement group_id="O2" value="1.71671" spread="0.203157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glx/Cr ratio anterior insula - post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7684" spread="0.30019"/>
                    <measurement group_id="O2" value="1.66124" spread="0.166421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Glu/Cr posterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.070</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.157</dispersion_value>
            <estimate_desc>Mean difference between the pre-dose (baseline) and post-dose values calculated as post-dose minus pre-dose (post minus pre).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Glu/Cr posterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.436</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Gln/Cr posterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.306</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Significance was set at p &lt;0.05.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Gln/Cr posterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.809</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Significance was set at p &lt;0.05.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Glx/Cr posterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Significance was set at p &lt;0.05.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.116</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.177</dispersion_value>
            <estimate_desc>Mean difference between the pre-dose (baseline) and post-dose values calculated as post-dose minus pre-dose (post minus pre).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Glx/Cr posterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.708</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.029</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.308</dispersion_value>
            <estimate_desc>Mean difference between the pre-dose (baseline) and post-dose values calculated as post-dose minus pre-dose (post minus pre).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Glu/Cr anterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.809</p_value>
            <p_value_desc>Significance was set at p &lt;0.050.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Glu/Cr anterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Gln/Cr anterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.960</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Significance was set at p &lt;0.05.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Gln/Cr anterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.937</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>Significance was set at p &lt;0.05.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Glx/Cr anterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.897</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Glx/Cr anterior insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.309</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals in Response to Blunt Pressure Pain: Percent Change in BOLD Activations Including Outliers</title>
        <description>BOLD fMRI imaging modality to assess brain activation signals across the whole brain in defined Region of Interest (ROI) brain regions in response to blunt pressure pain; acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kilograms [kg] pressure/equal stimulus conditions, and high pain pressure/up to 10 kg). Estimated as magnitude (percent change) of the betas representing brain signal activation associated with pressure induced pain. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS. Change from baseline for Period 1 and Period 2 summarized as Least Squares Mean (LS Mean). Abbreviation: Dorso Lateral Prefrontal Cortex (DLPFC).</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals in Response to Blunt Pressure Pain: Percent Change in BOLD Activations Including Outliers</title>
          <description>BOLD fMRI imaging modality to assess brain activation signals across the whole brain in defined Region of Interest (ROI) brain regions in response to blunt pressure pain; acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kilograms [kg] pressure/equal stimulus conditions, and high pain pressure/up to 10 kg). Estimated as magnitude (percent change) of the betas representing brain signal activation associated with pressure induced pain. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS. Change from baseline for Period 1 and Period 2 summarized as Least Squares Mean (LS Mean). Abbreviation: Dorso Lateral Prefrontal Cortex (DLPFC).</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.008" spread="0.0454"/>
                    <measurement group_id="O2" value="-0.024" spread="0.0454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brodman Area (BA) 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.050" spread="0.0709"/>
                    <measurement group_id="O2" value="0.029" spread="0.0709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BA40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="0.0436"/>
                    <measurement group_id="O2" value="0.026" spread="0.0436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left (L)_Anterior Insula (anIns)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.073" spread="0.0378"/>
                    <measurement group_id="O2" value="0.044" spread="0.0378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Amygdala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.040" spread="0.0502"/>
                    <measurement group_id="O2" value="0.041" spread="0.0502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Cerebellum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.0317"/>
                    <measurement group_id="O2" value="0.021" spread="0.0317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.0255"/>
                    <measurement group_id="O2" value="0.023" spread="0.0255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Mid Insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.0672"/>
                    <measurement group_id="O2" value="0.100" spread="0.0672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Mid Temporal Pole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.024" spread="0.0307"/>
                    <measurement group_id="O2" value="-0.044" spread="0.0307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Orbito Front</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.1000"/>
                    <measurement group_id="O2" value="-0.136" spread="0.1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Periaqueductal gray (PAG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.0351"/>
                    <measurement group_id="O2" value="0.016" spread="0.0351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Posterior Insula (pIns)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.0294"/>
                    <measurement group_id="O2" value="0.002" spread="0.0294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Posterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.132" spread="0.0414"/>
                    <measurement group_id="O2" value="-0.083" spread="0.0414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Precuneus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.057" spread="0.0281"/>
                    <measurement group_id="O2" value="-0.084" spread="0.0281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Putamen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.081" spread="0.0347"/>
                    <measurement group_id="O2" value="0.037" spread="0.0347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_Secondary Somatosensory Area (S2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.016" spread="0.0746"/>
                    <measurement group_id="O2" value="0.111" spread="0.0746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right (R)_DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.0467"/>
                    <measurement group_id="O2" value="0.101" spread="0.0467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Anterior Insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="0.0378"/>
                    <measurement group_id="O2" value="0.002" spread="0.0378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Amygdala</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.077" spread="0.0572"/>
                    <measurement group_id="O2" value="0.076" spread="0.0572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_BA23_base</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.0267"/>
                    <measurement group_id="O2" value="-0.017" spread="0.0267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Inferior Parietal Lobule (IPL)_base</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.042" spread="0.0301"/>
                    <measurement group_id="O2" value="-0.015" spread="0.0301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Insula_base</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.010" spread="0.0595"/>
                    <measurement group_id="O2" value="0.034" spread="0.0595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Mid Insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.0423"/>
                    <measurement group_id="O2" value="0.028" spread="0.0423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Mid Front_DLPFC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.0432"/>
                    <measurement group_id="O2" value="0.083" spread="0.0432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Mid Temporal Pole</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.048" spread="0.0250"/>
                    <measurement group_id="O2" value="-0.036" spread="0.0250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Orbito Front</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.046" spread="0.0709"/>
                    <measurement group_id="O2" value="-0.056" spread="0.0709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L_PAG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.034" spread="0.0349"/>
                    <measurement group_id="O2" value="0.011" spread="0.0349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Posterior Insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063" spread="0.0345"/>
                    <measurement group_id="O2" value="-0.024" spread="0.0345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Posterior Insula</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.050" spread="0.0434"/>
                    <measurement group_id="O2" value="-0.002" spread="0.0434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Posterior Cingulate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.175" spread="0.0476"/>
                    <measurement group_id="O2" value="-0.093" spread="0.0476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Precuneus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.070" spread="0.0332"/>
                    <measurement group_id="O2" value="-0.070" spread="0.0332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Precuneus_base</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.040" spread="0.0273"/>
                    <measurement group_id="O2" value="-0.038" spread="0.0273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Superior Temporal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.039" spread="0.0645"/>
                    <measurement group_id="O2" value="0.026" spread="0.0645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Premotor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.022" spread="0.0415"/>
                    <measurement group_id="O2" value="-0.022" spread="0.0415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Putamen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088" spread="0.0395"/>
                    <measurement group_id="O2" value="0.032" spread="0.0395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Primary Somatosensory Area (S1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.048" spread="0.0419"/>
                    <measurement group_id="O2" value="0.037" spread="0.0419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R_Thalamus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.010" spread="0.0245"/>
                    <measurement group_id="O2" value="0.018" spread="0.0245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Precuneus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.066" spread="0.0301"/>
                    <measurement group_id="O2" value="-0.078" spread="0.0301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Anterior Cingulate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6347</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1081</ci_lower_limit>
            <ci_upper_limit>0.1714</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BA22</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5181</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.079</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3356</ci_lower_limit>
            <ci_upper_limit>0.1771</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BA40</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2987</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2161</ci_lower_limit>
            <ci_upper_limit>0.0714</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_anIns</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5151</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.029</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0640</ci_lower_limit>
            <ci_upper_limit>0.1219</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_Amygdala</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2369</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.081</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2228</ci_lower_limit>
            <ci_upper_limit>0.0599</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_Cerebellum</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0758</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.077</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1642</ci_lower_limit>
            <ci_upper_limit>0.0092</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_DLPFC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4609</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.025</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0947</ci_lower_limit>
            <ci_upper_limit>0.0452</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_Mid Insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3813</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.111</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3745</ci_lower_limit>
            <ci_upper_limit>0.1524</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_Mid Temporal Pole</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7200</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.020</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0964</ci_lower_limit>
            <ci_upper_limit>0.1361</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_Orbito Front</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2099</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.168</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1065</ci_lower_limit>
            <ci_upper_limit>0.4434</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PAG</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9551</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.003</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1047</ci_lower_limit>
            <ci_upper_limit>0.0992</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Posterior Insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9940</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0855</ci_lower_limit>
            <ci_upper_limit>0.0848</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_Posterior Cingulate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4291</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1792</ci_lower_limit>
            <ci_upper_limit>0.0806</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_Precuneus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4670</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0496</ci_lower_limit>
            <ci_upper_limit>0.1028</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_Putamen</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4443</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0752</ci_lower_limit>
            <ci_upper_limit>0.1624</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_S2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2823</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.127</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3704</ci_lower_limit>
            <ci_upper_limit>0.1165</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_DLPFC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1369</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.105</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2481</ci_lower_limit>
            <ci_upper_limit>0.0378</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_anIns</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2376</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.078</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0573</ci_lower_limit>
            <ci_upper_limit>0.2127</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Amygdala</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0968</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.153</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3365</ci_lower_limit>
            <ci_upper_limit>0.0313</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_BA23_base</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5720</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.023</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0610</ci_lower_limit>
            <ci_upper_limit>0.1062</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_IPL_base</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5822</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.027</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1303</ci_lower_limit>
            <ci_upper_limit>0.0761</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Insula_base</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6851</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2697</ci_lower_limit>
            <ci_upper_limit>0.1824</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Mid Insula</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8656</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.013</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1699</ci_lower_limit>
            <ci_upper_limit>0.1446</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Mid Front_DLPFC</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1562</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.094</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2296</ci_lower_limit>
            <ci_upper_limit>0.0407</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Mid Temporal Pole</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7752</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0991</ci_lower_limit>
            <ci_upper_limit>0.0754</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Orbito Front</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9182</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.010</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1912</ci_lower_limit>
            <ci_upper_limit>0.2109</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>L_PAG</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6544</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.022</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0829</ci_lower_limit>
            <ci_upper_limit>0.1278</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_pIns</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0813</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.087</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0123</ci_lower_limit>
            <ci_upper_limit>0.1863</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_pIns</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4605</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.052</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0956</ci_lower_limit>
            <ci_upper_limit>0.2004</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Posterior Cingulate</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3136</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.081</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2484</ci_lower_limit>
            <ci_upper_limit>0.0856</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Precuneus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9929</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0885</ci_lower_limit>
            <ci_upper_limit>0.0893</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Precuneus_base</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9490</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0815</ci_lower_limit>
            <ci_upper_limit>0.0767</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Superior Temporal</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5668</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3019</ci_lower_limit>
            <ci_upper_limit>0.1722</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Premotor</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9958</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.000</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1398</ci_lower_limit>
            <ci_upper_limit>0.1391</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Putamen</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3379</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.057</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0659</ci_lower_limit>
            <ci_upper_limit>0.1795</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_S1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2186</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2262</ci_lower_limit>
            <ci_upper_limit>0.0565</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>R_Thalamus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8191</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>-0.008</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0843</ci_lower_limit>
            <ci_upper_limit>0.0678</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Precuneus</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7647</p_value>
            <p_value_desc>Significance was set at p &lt;0.05.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed-effect repeated measure model included participant as a random effect; treatment, visit as fixed effects.</method_desc>
            <param_type>Least Squares (LS) Mean difference</param_type>
            <param_value>0.012</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0698</ci_lower_limit>
            <ci_upper_limit>0.0930</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals in Response to a Control Visual (Checkerboard) Stimuli</title>
        <description>BOLD fMRI imaging modality to assess brain activation signals across the whole brain in defined ROI brain regions in response to checkerboard visual stimuli (flashing at 8 hertz [Hz]). Reported as percent change between the pre-dose (baseline) and post-dose values.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Voxel-wise Blood Oxygen Level Dependent (BOLD) Using Functional Magnetic Resonance Imaging (fMRI) of Brain Activation Signals in Response to a Control Visual (Checkerboard) Stimuli</title>
          <description>BOLD fMRI imaging modality to assess brain activation signals across the whole brain in defined ROI brain regions in response to checkerboard visual stimuli (flashing at 8 hertz [Hz]). Reported as percent change between the pre-dose (baseline) and post-dose values.</description>
          <population>FAS.</population>
          <units>percent change in BOLD signal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right (R) anterior mid insula cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.19"/>
                    <measurement group_id="O2" value="-0.05" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left (L) mid insula cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.20"/>
                    <measurement group_id="O2" value="0.00" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>R inferior parietal lobule, Brodman area 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.21"/>
                    <measurement group_id="O2" value="0.05" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>L inferior parietal lobule, Brodman area 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.27"/>
                    <measurement group_id="O2" value="0.02" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right primary somatosensory cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.14"/>
                    <measurement group_id="O2" value="-0.01" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left primary somatosensory cortex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.18"/>
                    <measurement group_id="O2" value="0.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left supplementary motor area</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.32"/>
                    <measurement group_id="O2" value="0.30" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resting State Brain Activity (Connectivity Analysis) Assessed by Temporal Correlations in Low Frequency fMRI BOLD Signals Across Pain Processing Regions</title>
        <description>Resting state brain activity assessed for correlation of brain seed region (pIns, anIns) to ROI connectivity at baseline (pre-dose) and post-dose (pre minus post) measured using z-score (mean of 0, standard deviation [SD] of 1); range approximately -3 to +3. Positive (+) z-scores reflect greater connectivity (+correlation between seed region and ROI). Negative (-) z-scores reflect -connectivity (anti-correlation between seed region and ROI). ROIs include PCC and IPL from within the default mode network (DMN). DMN is a constellation of regions in which connectivity is augmented in fibromyalgia.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>Participants in FAS with quality resting state data (data able to be corrected for motion [head and cardiorespiratory artifacts]).</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Resting State Brain Activity (Connectivity Analysis) Assessed by Temporal Correlations in Low Frequency fMRI BOLD Signals Across Pain Processing Regions</title>
          <description>Resting state brain activity assessed for correlation of brain seed region (pIns, anIns) to ROI connectivity at baseline (pre-dose) and post-dose (pre minus post) measured using z-score (mean of 0, standard deviation [SD] of 1); range approximately -3 to +3. Positive (+) z-scores reflect greater connectivity (+correlation between seed region and ROI). Negative (-) z-scores reflect -connectivity (anti-correlation between seed region and ROI). ROIs include PCC and IPL from within the default mode network (DMN). DMN is a constellation of regions in which connectivity is augmented in fibromyalgia.</description>
          <population>Participants in FAS with quality resting state data (data able to be corrected for motion [head and cardiorespiratory artifacts]).</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pIns_Posterior cingulate (PCC) pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1647" spread="1.71738"/>
                    <measurement group_id="O2" value="1.5405" spread="1.70926"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_PCC post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1504" spread="1.87564"/>
                    <measurement group_id="O2" value="1.2409" spread="2.29890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_primary motor region (M1) pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1486" spread="3.14585"/>
                    <measurement group_id="O2" value="1.3267" spread="1.94564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_M1 post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2605" spread="2.80878"/>
                    <measurement group_id="O2" value="1.3771" spread="2.01620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_cerebellum pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3984" spread="1.73000"/>
                    <measurement group_id="O2" value="1.4439" spread="1.46341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_cerebellum post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0213" spread="2.24014"/>
                    <measurement group_id="O2" value="1.0704" spread="2.66882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_Left (L) IPL 3a pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2025" spread="1.92233"/>
                    <measurement group_id="O2" value="-0.9296" spread="1.50499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_L IPL 3a post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3792" spread="2.18759"/>
                    <measurement group_id="O2" value="-1.2977" spread="1.37551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_L IPL 3b pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6552" spread="1.82208"/>
                    <measurement group_id="O2" value="1.7390" spread="2.00764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_L IPL 3b post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5614" spread="1.58417"/>
                    <measurement group_id="O2" value="0.9930" spread="2.50930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_Right (R) IPL 3b pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8310" spread="2.01819"/>
                    <measurement group_id="O2" value="0.7420" spread="1.57551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_R IPL 3b post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9766" spread="2.52679"/>
                    <measurement group_id="O2" value="0.9081" spread="2.18440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_cuneus pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1363" spread="1.97131"/>
                    <measurement group_id="O2" value="1.8543" spread="1.85494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pIns_cuneus post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0410" spread="1.84499"/>
                    <measurement group_id="O2" value="2.3324" spread="1.84622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anIns_L IPL pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1404" spread="2.21726"/>
                    <measurement group_id="O2" value="1.9982" spread="2.40790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anIns_L IPL post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6493" spread="2.04040"/>
                    <measurement group_id="O2" value="2.6797" spread="2.50765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anIns_R IPL pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6956" spread="2.61359"/>
                    <measurement group_id="O2" value="1.7848" spread="2.27345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anIns_R IPL post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2863" spread="1.31165"/>
                    <measurement group_id="O2" value="2.6194" spread="2.37251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anIns_S2 pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6592" spread="1.69160"/>
                    <measurement group_id="O2" value="1.6799" spread="1.64784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anIns_S2 post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1466" spread="2.13680"/>
                    <measurement group_id="O2" value="2.4225" spread="2.68238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anIns_cuneus pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5103" spread="2.48669"/>
                    <measurement group_id="O2" value="1.7550" spread="1.65232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>anIns_cuneus post-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8042" spread="2.08443"/>
                    <measurement group_id="O2" value="1.1899" spread="1.67701"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gracely Box Scales for Pain Intensity (GBSint) Including Outliers</title>
        <description>Minimum and maximum pain intensity acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kg pressure/equal stimulus conditions, and high pain pressure/up to 10 kg) measured during fMRI and scored from 0 (no pain sensation) to 20 (extremely intense). Baseline and Post-dose data for Period 1 and Period 2 summarized as Least Squares Mean (LS Mean). Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Gracely Box Scales for Pain Intensity (GBSint) Including Outliers</title>
          <description>Minimum and maximum pain intensity acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kg pressure/equal stimulus conditions, and high pain pressure/up to 10 kg) measured during fMRI and scored from 0 (no pain sensation) to 20 (extremely intense). Baseline and Post-dose data for Period 1 and Period 2 summarized as Least Squares Mean (LS Mean). Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minimum pain intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1184" spread="0.6535"/>
                    <measurement group_id="O2" value="3.4725" spread="0.6535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum pain intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5701" spread="0.6953"/>
                    <measurement group_id="O2" value="15.6117" spread="0.6953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gracely Box Scales for Pain Unpleasantness (GBSunp) Including Outliers</title>
        <description>Minimum and maximum pain unpleasantness acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kg pressure/equal stimulus conditions, and high pain pressure/up to 10 kg) measured during fMRI and scored from 0 (neutral) to 20 (very intolerable). Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline/Pre-dose (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Gracely Box Scales for Pain Unpleasantness (GBSunp) Including Outliers</title>
          <description>Minimum and maximum pain unpleasantness acquired during resting state (no evoked pain) and during evoked pain (thumb pressure device with non-painful pressure, 2 kg pressure/equal stimulus conditions, and high pain pressure/up to 10 kg) measured during fMRI and scored from 0 (neutral) to 20 (very intolerable). Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minimum pain unpleasantness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3924" spread="0.5803"/>
                    <measurement group_id="O2" value="3.4258" spread="0.5803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum pain unpleasantness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1576" spread="0.8294"/>
                    <measurement group_id="O2" value="11.2742" spread="0.8294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: 7 Day Average Pain Score Including Outliers</title>
        <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The 7 day average pain score was defined as the mean daily pain NRS value for the last 7 days prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: 7 Day Average Pain Score Including Outliers</title>
          <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The 7 day average pain score was defined as the mean daily pain NRS value for the last 7 days prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1014" spread="0.4104"/>
                    <measurement group_id="O2" value="4.7038" spread="0.4104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: 3 Day Average Pain Score Including Outliers</title>
        <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The 3 day average pain score was defined as the mean daily pain NRS value for the last 3 days prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: 3 Day Average Pain Score Including Outliers</title>
          <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The 3 day average pain score was defined as the mean daily pain NRS value for the last 3 days prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3467" spread="0.4436"/>
                    <measurement group_id="O2" value="4.7745" spread="0.4436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: Individual Daily Pain Score Including Outliers</title>
        <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The individual daily pain score was defined as the final score recorded in the last pain diary of the treatment period 24 hours prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Daily Pain Diary Numeric Rating Scale (NRS) Item From the Modified Brief Pain Inventory (mBPI) for Assessment of Clinical Pain: Individual Daily Pain Score Including Outliers</title>
          <description>The daily pain diary consisted of the mBPI item regarding participant-rated average of pain over the past 24 hours. Scored on an 11-point numeric scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The individual daily pain score was defined as the final score recorded in the last pain diary of the treatment period 24 hours prior to fMRI scanning visit. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3110" spread="0.4787"/>
                    <measurement group_id="O2" value="5.0527" spread="0.4787"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-Form McGill Pain Questionnaire (SF-MPQ): Affective Total Score Including Outliers</title>
        <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12); higher scores indicated higher pain/impact. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-Form McGill Pain Questionnaire (SF-MPQ): Affective Total Score Including Outliers</title>
          <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12); higher scores indicated higher pain/impact. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4100" spread="0.3095"/>
                    <measurement group_id="O2" value="1.8173" spread="0.3095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-Form McGill Pain Questionnaire (SF-MPQ): Sensory Total Score Including Outliers</title>
        <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12); higher scores indicated higher pain/impact. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-Form McGill Pain Questionnaire (SF-MPQ): Sensory Total Score Including Outliers</title>
          <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12); higher scores indicated higher pain/impact. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6641" spread="1.0759"/>
                    <measurement group_id="O2" value="9.4722" spread="1.0759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospital Anxiety and Depression Scale (HADS): Anxiety Total Score Including Outliers</title>
        <description>A participant rated questionnaire with 2 subscales. HADS-A assessed state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assessed state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicated greater severity of anxiety and depression symptoms. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Anxiety and Depression Scale (HADS): Anxiety Total Score Including Outliers</title>
          <description>A participant rated questionnaire with 2 subscales. HADS-A assessed state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assessed state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicated greater severity of anxiety and depression symptoms. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3896" spread="0.6132"/>
                    <measurement group_id="O2" value="5.1558" spread="0.6132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hospital Anxiety and Depression Scale (HADS): Depression Total Score Including Outliers</title>
        <description>A participant rated questionnaire with 2 subscales. HADS-A assessed state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assessed state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicated greater severity of anxiety and depression symptoms. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Anxiety and Depression Scale (HADS): Depression Total Score Including Outliers</title>
          <description>A participant rated questionnaire with 2 subscales. HADS-A assessed state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assessed state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicated greater severity of anxiety and depression symptoms. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1750" spread="0.4147"/>
                    <measurement group_id="O2" value="3.8705" spread="0.4147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pain Catastrophizing Scale (PCS) Including Outliers</title>
        <description>PCS is a participant rated 13-item instrument to measure the presence and severity of catastrophizing. Scored 0 (not at all) to 4 (all the time) to statements such as &quot;When I'm in painI worry all the time about whether the pain will end&quot;. All 13 statements start with &quot;When I'm in pain&quot;. Total score ranged from 0 to 52; higher scores reflected greater impairment. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Catastrophizing Scale (PCS) Including Outliers</title>
          <description>PCS is a participant rated 13-item instrument to measure the presence and severity of catastrophizing. Scored 0 (not at all) to 4 (all the time) to statements such as &quot;When I'm in painI worry all the time about whether the pain will end&quot;. All 13 statements start with &quot;When I'm in pain&quot;. Total score ranged from 0 to 52; higher scores reflected greater impairment. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4050" spread="1.0192"/>
                    <measurement group_id="O2" value="12.0041" spread="1.0192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-Form McGill Pain Questionnaire (SF-MPQ): Overall Score Including Outliers</title>
        <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by the participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12). Total (overall) score was sum of items 1 to 15, range 0 to 45; higher scores indicated higher pain/impact. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
        <time_frame>Baseline (Day 8, Day 37), Post-dose (Period 1/Day 22, Period 2/Day 51)</time_frame>
        <population>FAS. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean.</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-Form McGill Pain Questionnaire (SF-MPQ): Overall Score Including Outliers</title>
          <description>SF-MPQ was completed to assess pain over the past week and to assess present pain and consists of 15 pain descriptors: sensory dimension of pain experience (sum of items 1 to 11) and affective dimension (sum of items 12 to 15). Each descriptor was ranked by the participant on a 4-point intensity scale (0=none to 3=severe) and totaled in each subclass (sensory range 0 to 33; affective range 0 to 12). Total (overall) score was sum of items 1 to 15, range 0 to 45; higher scores indicated higher pain/impact. Any observation with a studentized residual &gt;3 or &lt;-3 was considered an outlier.</description>
          <population>FAS. Baseline and Post-dose data for Period 1 and Period 2 summarized as LS Mean.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0862" spread="1.2657"/>
                    <measurement group_id="O2" value="11.2774" spread="1.2657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sphygmomanometry Evoked Allodynia in Relation to the Blood Pressure (BP) Value at Which Allodynia Was Evoked</title>
        <description>BP cuff evoked allodynia assessed based on participant response to the following question &quot;When I take your blood pressure, tell me if the cuff's pressure is painful&quot;. A standard BP cuff was inflated at approximately 10 millimeters of mercury (mm Hg) per second up to 180 mm Hg or to point when participant experienced pain; performed 3 times on each arm whether or not pain was reported. If no pain elicited at 180 mm Hg, it was recorded that no sphygmomanometry-evoked allodynia occurred. If pain was reported, value (in mm Hg) at which pain first occured was recorded for each of the assessments.</description>
        <time_frame>Day 58</time_frame>
        <population>FAS; N=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Treatment: Pregabalin, Placebo</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.
Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Sphygmomanometry Evoked Allodynia in Relation to the Blood Pressure (BP) Value at Which Allodynia Was Evoked</title>
          <description>BP cuff evoked allodynia assessed based on participant response to the following question &quot;When I take your blood pressure, tell me if the cuff's pressure is painful&quot;. A standard BP cuff was inflated at approximately 10 millimeters of mercury (mm Hg) per second up to 180 mm Hg or to point when participant experienced pain; performed 3 times on each arm whether or not pain was reported. If no pain elicited at 180 mm Hg, it was recorded that no sphygmomanometry-evoked allodynia occurred. If pain was reported, value (in mm Hg) at which pain first occured was recorded for each of the assessments.</description>
          <population>FAS; N=number of participants with analyzable data at observation.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Left Arm BP Cuff Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.92" spread="19.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Right Arm BP Cuff Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.31" spread="19.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain at the Bilateral Epicondyle Tender Points Assessed Using American College of Rheumatology (ACR) Classification Criteria</title>
        <description>Participant rated severity of pain upon application of 4 kilograms (kg) pressure via dolorimeter at the bilateral epicondyle tender points (2 tender points, 2 centimeters distal to the epicondyles) described in the American College of Rheumatology (ACR) classification criteria and scored on a 0 (no pain) to 10 (worst possible pain) rating scale. Each arm was to be assessed for any pain (one point on each arm) with the application of pressure.</description>
        <time_frame>Day 58</time_frame>
        <population>FAS; N=number of participants with analyzable data at observation.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Treatment: Pregabalin, Placebo</title>
            <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.
Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain at the Bilateral Epicondyle Tender Points Assessed Using American College of Rheumatology (ACR) Classification Criteria</title>
          <description>Participant rated severity of pain upon application of 4 kilograms (kg) pressure via dolorimeter at the bilateral epicondyle tender points (2 tender points, 2 centimeters distal to the epicondyles) described in the American College of Rheumatology (ACR) classification criteria and scored on a 0 (no pain) to 10 (worst possible pain) rating scale. Each arm was to be assessed for any pain (one point on each arm) with the application of pressure.</description>
          <population>FAS; N=number of participants with analyzable data at observation.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Severity Left Epicondyle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="2.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Severity Right Epicondyle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72" spread="2.671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events (all causalities) were reported from the time of first dose of study treatment up to 28 days after last dose of study treatment.</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin</title>
          <description>Pregabalin administered in Period 1 (75 mg BID Period 1/Day 9 to 11; then 150 mg BID Period 1/Day 12 to 16; then 200 mg BID Period 1/Day 17 to 19; then 225 mg BID Period 1/Day 20 to 22) or administered in Period 2 (75 mg BID Period 2/Day 38 to 40; then 150 mg BID Period 2/Day 41 to 45; then 200 mg BID Period 2/Day 46 to 48; then 225 mg BID Period 2/Day 49 to 51); then taper Period 2/Day 52 to 58.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo to match study treatment administered in Period 1 or Placebo to match study treatment administered in Period 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device material issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

